Épisode 37 : Étude DAPA-CKD
Dapagliflozine chez les sujets avec insuffisance rénale chronique et macroalbuminurie (étude DAPA-CKD)
Diffusé le 21 octobre 2020
Dans cette 37e baladodiffusion, les Drs Luc Lanthier et Mélanie Masse discutent de l’efficacité de la dapagliflozine dans le traitement des sujets avec insuffisance rénale chronique et macroalbuminurie, en plus de réviser la littérature médicale de septembre 2020.
Référence principale
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46. PubMed PMID: 32970396.
Article résumé
Lanthier L, Masse M, Plourde MÉ, Cauchon M. Chez les sujets avec insuffisance rénale chronique modérée et macroalbuminurie, diabétiques ou non, est-ce que la dapagliflozine amène un bénéfice rénal et cardiovasculaire comparativement au placébo ? Rev Med Interne. 2021;42(1):65-66. PubMed PMID: 33309055.
Articles associés
Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973-87. PubMed PMID: 32497510.
Naylor KL, Kim SJ, McArthur E, Garg AX, McCallum MK, Knoll GA. Mortality in Incident Maintenance Dialysis Patients Versus Incident Solid Organ Cancer Patients: A Population-Based Cohort. Am J Kidney Dis. 2019;73(6):765-776. PubMed PMID: 30738630.
Filion KB, Lix LM, Yu OH, Dell'Aniello S, Douros A, Shah BR, et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ. 2020;370:m3342. PubMed PMID: 32967856.
Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Ann Intern Med. 2020;173(4):278-286. PubMed PMID: 32598218.
Autres articles d'intérêt récents
Lacasse Y, Series F, Corbeil F, Baltzan M, Paradis B, Simao P, et al. Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2020;383(12):1129-38. PubMed PMID: 32937046.
Yao TC, Huang YW, Chang SM, Tsai SY, Wu AC, Tsai HJ. Association Between Oral Corticosteroid Bursts and Severe Adverse Events : A Nationwide Population-Based Cohort Study. Ann Intern Med. 2020;173(5):325-30. PubMed PMID: 32628532.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al; VERTIS CV Investigators. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425-35. PubMed PMID: 32966714.
Guide de pratique récents
Ko CW, Siddique SM, Patel A, Harris A, Sultan S, Altayar O, et al. AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. Gastroenterology. 2020;159(3):1085-94. PubMed PMID: 32810434.
Référence du quiz clinique
Camaschella C. Iron deficiency. Blood. 2019 Jan 3;133(1):30-39. PubMed PMID: 30401704.
DeLoughery TG. Iron Deficiency Anemia. Med Clin North Am. 2017;101(2):319-32. PubMed PMID: 28189173.
Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, Moretti D, Zimmermann MB. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017;4(11):e524-e533. PubMed PMID: 29032957.
Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica. 2020;105(5):1232-39. PubMed PMID: 31413088.